Bergen, Norway, December 15th, 2023, Today, Lifecare AS (LIFE), a clinical
stage medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), informs that the formal relationship with the Company's Chief
Scientific Officer (CSO) will be adjusted from an consultancy agreement to an
employment agreement.
Since 2013, Prof. Dr. Dr. Med. Andreas Pfützner has been engaged in the role
of CSO in Lifecare. The professional relationship has so far been based on a
management-for-hire contract through his wholly owned and controlled company
Islay Ventures GmbH ("IV"). Aligned with Lifecare's long term strategy, Prof.
Pfützner will now act as the Company's CSO based on an employment
relationship, with effect from January 1st, 2024.
Prof. Pfützner is a highly recognized diabetologist and runs a diabetes
research institute co-located with Lifecare Laboratory GmbH in Mainz, Germany.
Prof. Pfützner has more than 30 years of experience with development of
medical devices and products primarily related to diabetes and diabetes
technology. He is a teaching professor at DTMD University in Luxembourg and
the University of Bingen, Germany.
For many years, Prof. Pfützner has been an attractive and sought-after speaker
at highly recognized and professionally relevant arenas. This naturally has
positive ripple effects for Lifecare and has also opened the doors to academic
circles, which have been of great benefit to the Company.
- Prof. Pützner has had a very important position at Lifecare for a decade and
will permanently continue to do so. While the formal adjustment into an
employment agreement implies no practical changes in the daily business of the
Company and our projects, it indicates an even stronger commitment of the CSO
and we are very pleased to conclude the formal connection into an employment
relationship. This adjustment is in line with Lifecare's long term strategy
and not least secure the base of essential key personnel, says Joacim Holter,
Lifecare CEO.
About us
Lifecare AS is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52